Blue Trust Inc. Acquires 1,380 Shares of Vaxcyte, Inc. $PCVX

Blue Trust Inc. boosted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 176.7% in the 2nd quarter, Holdings Channel.com reports. The firm owned 2,161 shares of the company’s stock after purchasing an additional 1,380 shares during the quarter. Blue Trust Inc.’s holdings in Vaxcyte were worth $70,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in PCVX. RA Capital Management L.P. boosted its stake in Vaxcyte by 40.3% during the 1st quarter. RA Capital Management L.P. now owns 12,189,149 shares of the company’s stock valued at $460,262,000 after purchasing an additional 3,499,959 shares during the period. Wellington Management Group LLP boosted its stake in Vaxcyte by 44.4% during the 1st quarter. Wellington Management Group LLP now owns 6,416,930 shares of the company’s stock valued at $242,303,000 after purchasing an additional 1,972,918 shares during the period. Baker BROS. Advisors LP boosted its stake in Vaxcyte by 1,211.0% during the 1st quarter. Baker BROS. Advisors LP now owns 640,885 shares of the company’s stock valued at $24,200,000 after purchasing an additional 592,000 shares during the period. Nuveen LLC bought a new stake in Vaxcyte during the 1st quarter valued at approximately $20,988,000. Finally, Fiera Capital Corp bought a new stake in Vaxcyte during the 1st quarter valued at approximately $13,563,000. Institutional investors own 96.78% of the company’s stock.

Analyst Ratings Changes

PCVX has been the subject of several recent analyst reports. The Goldman Sachs Group started coverage on Vaxcyte in a research note on Friday, September 12th. They set a “neutral” rating and a $38.00 target price for the company. Cowen reiterated a “buy” rating on shares of Vaxcyte in a research report on Thursday, August 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $106.25.

Vaxcyte Trading Down 2.8%

Shares of PCVX opened at $42.39 on Friday. Vaxcyte, Inc. has a 1 year low of $27.66 and a 1 year high of $116.53. The stock has a 50 day simple moving average of $34.60 and a 200-day simple moving average of $33.72. The stock has a market cap of $5.50 billion, a PE ratio of -10.31 and a beta of 1.12.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.10). During the same quarter in the previous year, the business earned ($1.10) earnings per share. On average, sell-side analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.